A California woman has filed a Zoloft lawsuit alleging the manufacturer of the drug committed fraud by marketing the drug as effective. Laura Plumlee has said that Pfizer withheld studies from the Food and Drug Administration (FDA) indicating that the antidepressant drug is about as effective as a placebo. Many studies have also linked the drug to potentially severe birth defects.
Read more about birth defects caused by Zoloft use during pregnancy...
Showing posts with label The Food and Drug Administration. Show all posts
Showing posts with label The Food and Drug Administration. Show all posts
February 20, 2013
Zoloft lawsuit accuses manufacturers of fraud
November 20, 2012
Acupuncture may be more effective at reducing migraines than Topamax
A study conducted in Taiwanhas found that acupuncture may be more effective at reducing migraine headaches than topiramate, the active ingredient in Topamax. Topamax side effects include heart and memory complications, as well as congenital birth defects among women who use the drug while pregnant.
Read more about birth defects linked to Topamax use...
Read more about birth defects linked to Topamax use...
November 14, 2012
European regulators won’t recommend weight loss drug containing Topamax ingredient
The European Medicines Agency (EMA) has recommended not to approve a new weight loss drug containing topiramate, the active drug in Topamax. The EMA expressed concerns about the long-term risks of cardiovascular problems and other side effects associated with the drug, known as Qsymia. Topamax was recently upgraded to the FDA’s Pregnancy Category D, signifying the drug has a proven risk of causing birth defects.
Read more about the risks associated with Qsymia...
Read more about the risks associated with Qsymia...
October 24, 2012
Forest Laboratories files for FDA approval of new antidepressant drug
Forest Laboratories has filed for marketing approval from the Food and Drug Administration (FDA) for its new antidepressant drug levomilnacipran, which is in the same class of drugs as the antidepressant Effexor. The drugs are classified as serotonin norepinephrine reuptake inhibitors (SNRIs).
Read more about new SNRI antidepressant...
Read more about new SNRI antidepressant...
October 2, 2012
Drug maker receives approval for generic Lexapro
Indian drug maker Lupin Pharmaceuticals has received final approval from the Food and Drug Administration to sell its generic form of the antidepressant Lexapro in the U.S. The company is among the first to receive approval.
Subscribe to:
Posts (Atom)